15
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Targeted Screening of Adult First-Degree Relatives for Chronic Kidney Disease and Its Risk Factors

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: First-degree relatives (FDRs) of chronic kidney disease (CKD) patients have a high prevalence of CKD and its risk factors. We evaluated adult FDRs of end-stage renal disease (ESRD) patients for the prevalence of CKD and its risk factors. Methods: Adult FDRs of ESRD patients were screened. Patients <18 years of age with CKD due to polycystic kidney disease, diabetic nephropathy and urological disease were excluded. Age, sex, hypertension, weight, blood pressure, urine analysis, fasting blood glucose, serum creatinine and cholesterol were done. Results: 606 FDRs of 145 index patients were screened; mean age was 39.8 years and 53.3% were male, 26 obese and 122 overweight. 29.7% had hypertension and 3.6% diabetes mellitus. Screening identified new cases of hypertension (21.5%), diabetes mellitus (2.0%), impaired fasting glucose (22.4%) and hypercholesterolemia (18.8%). 5.9% had proteinuria (≧1+). 61.2% of FDRs had eGFR in stage 1, 34.7% in stage 2, 3.6% in stage 3, and 0.5% in stage 4–5. 8.6% had CKD (88.5% were unaware). On multivariate analysis, older age, female sex, proteinuria and uncontrolled blood pressure had a significant association with eGFR <60 ml/min/1.73 m<sup>2</sup>. Conclusion: In India, CKD and its risk factors show a familial clustering, and screening of FDRs of ESRD patients will be a viable option for a CKD preventive program.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Obesity-related glomerulopathy: an emerging epidemic.

          We report the first large renal biopsy-based clinicopathologic study on obesity-related glomerulopathy. Obesity was defined as body mass index (BMI)> 30 kg/m2. Obesity-related glomerulopathy (ORG) was defined morphologically as focal segmental glomerulosclerosis and glomerulomegaly (O-FSGS; N = 57) or glomerulomegaly alone (O-GM; N = 14). Review of 6818 native renal biopsies received from 1986 to 2000 revealed a progressive increase in biopsy incidence of ORG from 0.2% in 1986-1990 to 2.0% in 1996-2000 (P = 0.0001). Mean BMI in ORG was 41.7 (range 30.9 to 62.7). Indications for renal biopsy included proteinuria (N = 40) or proteinuria and renal insufficiency (N = 31). Seventy-one patients with ORG were compared to 50 patients with idiopathic FSGS (I-FSGS). Patients with ORG were older (mean 42.9 vs. 32.6 years, P < 0.001) and more often Caucasian (75% vs. 52%; P = 0.003). ORG patients had a lower incidence of nephrotic range proteinuria (48% vs. 66%; P = 0.007) and nephrotic syndrome (5.6% vs. 54%; P < 0.001), with higher serum albumin (3.9 vs. 2.9 g/dL; P < 0.001), lower serum cholesterol (229 vs. 335 mg/dL; P < 0.001), and less edema (35% vs. 68%; P = 0.003). On renal biopsy, patients with ORG had fewer lesions of segmental sclerosis (10 vs. 39%; P < 0.001), more glomerulomegaly (100% vs. 10%; P < 0.001), and less extensive foot process effacement (40 vs. 75%; P < 0.001). Glomerular diameter in ORG (mean 226 mu) was significantly larger than age- and sex-matched normal controls (mean 168 mu; P < 0.001). Follow-up was available in 56 ORG patients (mean 27 months) and 50 idiopathic FSGS controls (mean 38 months). A total of 75% of ORG patients received angiotensin-converting enzyme (ACE) inhibition or A2 blockade while 78% of the I-FSGS patients received immunosuppressive therapy. ORG patients had less frequent doubling of serum creatinine (14.3% vs. 50%; P < 0.001) and progression to ESRD (3.6% vs. 42%; P < 0.001). On multivariate analysis, presenting serum creatinine and severity of proteinuria were the only predictors of poor outcome in ORG. ORG is distinct from idiopathic FSGS, with a lower incidence of nephrotic syndrome, more indolent course, consistent presence of glomerulomegaly, and milder foot process fusion. The ten-fold increase in incidence over 15 years suggests a newly emerging epidemic. Heightened physician awareness of this entity is needed to ensure accurate diagnosis and appropriate therapy.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Chronic kidney disease in the developing world.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.

                Bookmark

                Author and article information

                Journal
                NEC
                Nephron Clin Pract
                10.1159/issn.1660-2110
                Nephron Clinical Practice
                S. Karger AG
                1660-2110
                2010
                September 2010
                21 May 2010
                : 116
                : 2
                : c128-c136
                Affiliations
                Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India
                Article
                314662 Nephron Clin Pract 2010;116:c128–c136
                10.1159/000314662
                20502049
                f93c2943-2ad8-4be4-815d-e33ec21fb2d4
                © 2010 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 25 October 2009
                : 29 January 2010
                Page count
                Figures: 1, Tables: 8, References: 34, Pages: 1
                Categories
                Original Paper

                Cardiovascular Medicine,Nephrology
                End-stage renal disease,First-degree relatives,Chronic kidney disease

                Comments

                Comment on this article